FindTrial
Sign In

An open label, Phase II study of biweekly VELCADETM and intermittent CAELIXTM in patients with ovarian cancer failing platinum containing regimens

An open label, Phase II study of biweekly VELCADETM and intermittent CAELIXTM in patients with ovarian cancer failing platinum containing regimens

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-003962-40-IT
Enrollment
Unknown
Registered
2007-01-15
Start date
2006-03-22
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer failing platinum containing regimens MedDRA version: 9.1 Level: LLT Classification code 10061535 Term: Ovarian neoplasm

Interventions

Trade Name: Velcade Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Bortezomib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Tra

Sponsors

FONDAZIONE SENDO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026